1. Scrip
  2. >>Business

Cipla Moves Into mRNA Arena With Stake In German Biotech Ethris

 
• By Anju Ghangurde

Cipla set to hold 10.35% in biotech Ethris, which is progressing inhaled mRNA-based therapies, among other key assets. The Indian firm expects its next wave of growth to come from areas like biosimilars and mRNA alongside lung leadership aspirations, putting the spotlight on the broader direction of the deal.

Cipla-Ethris ally to develop mRNA-based therapies • Source: Shutterstock

Cipla Limited’s efforts to shepherd Moderna, Inc.’s messenger RNA (mRNA) COVID-19 vaccine to India may not have gone as per plan in 2021, but the Indian company isn’t going to sit on the sidelines anymore and watch the action build around the promising new star modality.(Also see "More Indian Firms Dip Toes In Vaccines Segment: Just 'Opportunistic'?" - Scrip, 3 January, 2022.)(Also see "Tracing Cipla’s Interest In Vaccines, Potential For Tie-Up With Moderna" - Scrip, 28 May, 2021.)

The Mumbai-based firm has, via its wholly owned UK subsidiary, Cipla (EU) Limited, entered into definitive agreements to acquire about 10

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

More from Scrip